BioSpace News Archive

Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).1

Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announces that management will present at the following investor conferences

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has approved a $3.0 million stock repurchase authorization, effective as of May 26, 2021.

Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Nautilus’ management is scheduled to present on Thursday, June 10th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time.

IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA a commercial-stage innovative molecular diagnostics company, held its annual general shareholders’ meeting and an extraordinary general shareholders’ meeting

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company participated in a late-cycle meeting with the U.S. Food and Drug Administration (“FDA”) yesterday.

Illumina, Inc. announced that its executives will be speaking at the following investor conference

Synbal, Inc., a privately held biotechnology company specializing in the development of genetically complex, humanized mouse models for research announced today that they have received a SBIR grant from the National Institute of Allergy and Infectious Diseases to develop a novel, humanized mouse model for Covid-19 therapeutics research.

Olympus Corporation (”Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its decision to exercise the call option in February, 2021